The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients

Coban E., Sari R.

ENDOCRINE RESEARCH, cilt.30, sa.3, ss.343-349, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 3
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1081/erc-200033541
  • Dergi Adı: ENDOCRINE RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.343-349
  • Anahtar Kelimeler: fenofibrate, C-reactive protein, obesity, anti-inflammatory effect, CORONARY-HEART-DISEASE, CARDIOVASCULAR RISK, ENDOTHELIAL FUNCTION, INSULIN SENSITIVITY, METABOLIC SYNDROME, CIPROFIBRATE, SIMVASTATIN, PARAMETERS, EFFICACY, THERAPY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

It is now well documented that obesity is associated with a chronic low-grade inflammatory state. Levels of high-sensitivity C-reactive protein, a marker of systemic inflammation and a mediator of atherothrombotic disease, have been shown to correlate with cardiovascular disease risk. Our objective was to evaluate the effect of fenofibrate on the levels of high-sensitivity C-reactive protein in dyslipidemic obese patients. We selected 30 dyslipidemic obese patients (body mass index greater than or equal to 30 kg/m(2)) and 20 normolipidemic, nonobese healthy subjects. Dyslipidemic obese patients were treated with fenofibrate 200 mg/day for 3 months. Serum high-sensitivity C-reactive protein and metabolic parameters were evaluated at baseline in both groups and after fenofibrate treatment in dyslipidemic obese patients. At baseline, significantly higher high-sensitivity C-reactive protein levels were found in dyslipidemic obese patients than normal subjects (0.58 +/- 0.3 vs 0.14 +/- 0.1 mg/dL, P < 0.01). Total cholesterol, low-density lipoprotein cholesterol, and triglyceride decreased significantly (P < 0.05, P < 0.05, and P < 0.01, respectively), and levels of high-density lipoprotein cholesterol significantly increased (P < 0.05) after treatment with fenofibrate in the dyslipidemic obese group. Levels of high-sensitivity C-reactive protein decreased significantly (approximately 74.1%) after fenofibrate treatment from a mean of 0.58 +/- 0.3 mg/dL to 0.15 +/- 0.2 mg/dL, P < 0.01. Our findings suggest that fenofibrate may be used as a first-line therapy for improving the plasma lipids profile, as well as the chronic low-grade inflammatory state in dyslipidemia and obesity.